carrolee_barlow_md_phd_chief_executive_officer_of_the_parkinsons_institute__clinical_center

New chief executive for Parkinson’s Institute

pharmafile | March 6, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Carrolee Barlow, Parkinson’s Institute 

The Parkinson’s Institute and Clinical Center has appointed neuroscience and neurodegeneration expert Dr Carrolee Barlow as its new chief executive.

Barlow is only the second chief executive in the Institute’s 25 year history and takes over from Dr William Langston, who founded the organisation in 1988 and has led it ever since. Langston will now continue as its chief scientific officer.

Barlow’s previous work has spanned clinical care, laboratory and clinical research, academia, and industry. She is the former chief scientific officer and chief medical officer of biotech firm BrainCells in San Diego, California.

Advertisement

Prior to BrainCells she served as the director of Molecular Neuroscience and Therapeutic Area Head for Stroke and Neurodegeneration at Merck.

Langston said: “We are exceptionally fortunate to have attracted and recruited Dr Barlow, and her credentials are beyond impressive. With both a PhD and MD, and extensive research, drug development, and clinical trials experience, I can’t imagine a better fit for this position and the Parkinson’s Institute.”

Barlow added: “Two and a half decades ago, Dr Langston and fellow Parkinson’s disease experts set out to create a better way to research the disease and care for people living with Parkinson’s. Today, I am proud to have joined an organisation with such a rich history and demonstrated impact on Parkinson’s disease care and treatment.” 

Related Content

No items found
The Gateway to Local Adoption Series

Latest content